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Abstract: Background: This methodological paper presents both a scientific rationale and a
methodological approach for investigating the effects of resveratrol supplementation on mood
and cognitive performance in postmenopausal women. Postmenopausal women have an increased
risk of cognitive decline and dementia, which may be at least partly due to loss of beneficial effects
of estrogen on the cerebrovasculature. We hypothesise that resveratrol, a phytoestrogen, may
counteract this risk by enhancing cerebrovascular function and improving regional blood flow in
response to cognitive demands. A clinical trial was designed to test this hypothesis. Method:
Healthy postmenopausal women were recruited to participate in a randomised, double-blind,
placebo-controlled (parallel comparison) dietary intervention trial to evaluate the effects of resveratrol
supplementation (75 mg twice daily) on cognition, cerebrovascular responsiveness to cognitive
tasks and overall well-being. They performed the following tests at baseline and after 14 weeks
of supplementation: Rey Auditory Verbal Learning Test, Cambridge Semantic Memory Battery,
the Double Span and the Trail Making Task. Cerebrovascular function was assessed simultaneously by
monitoring blood flow velocity in the middle cerebral arteries using transcranial Doppler ultrasound.
Conclusion: This trial provides a model approach to demonstrate that, by optimising circulatory
function in the brain, resveratrol and other vasoactive nutrients may enhance mood and cognition and
ameliorate the risk of developing dementia in postmenopausal women and other at-risk populations.
Keywords: resveratrol; vasoactive nutrients; postmenopausal; cognition; mood; physical function;
healthy ageing; cerebrovascular function; transcranial Doppler ultrasound
1. Introduction
Dementia disproportionately affects older women (47% by the age of 85 years, compared with 31%
of men). It not only destroys cognitive capabilities but also deprives individuals of their independence
and places emotional and financial burdens on families, caregivers and society at large. Dementia is
predicted to be the top health crisis in this century, outpacing heart disease and cancer in terms of
years lost due to disability and there is currently no cure nor means of slowing its progression [1].
Furthermore, there tends to be a substantial gap between the noticeable symptoms of cognitive decline
and when medical advice is sought, and a further delay before dementia is diagnosed. In Australia,
it takes an average of three years from presentation of first symptoms to diagnosis [2]. As such,
quality of life in the later years is likely to be sub-optimal due to impaired cognition. Cognitive
impairment may also contribute to decline in physical functioning, such as activities of daily living,
Nutrients 2016, 8, 150; doi:10.3390/nu8030150 www.mdpi.com/journal/nutrients
Nutrients 2016, 8, 150 2 of 14
and is associated with increased risk of falls in the elderly [3]. Early intervention to maintain high-level
cognitive function and well-being may help prolong independent living in older adults. Therefore,
it is important to identify feasible lifestyle strategies to counteract cognitive decline in ageing women.
1.1. Estrogen, Menopause and Dementia
While women enjoy longer life expectancy, this may not be the only reason for the higher risk
of dementia in elderly women. Growing evidence has shown that loss of estrogen after menopause
may lead to accelerated deficits in brain function, which may lead to higher risk of dementia [4].
Ageing and many lifestyle diseases are closely related to poor blood circulatory function, including
poor perfusion of brain regions. Estrogen targets blood vessels to promote blood flow in the heart,
skeletal muscle and particularly in the brain to support cognitive and affective functions. Estrogen
binding to estrogen receptors (ER) activates endothelial nitric oxide synthase (eNOS), modulating
nitric oxide (NO)-mediated vasodilatation to meet tissue perfusion demands for optimal functioning.
Importantly, ER-β are abundantly expressed in the hippocampus, a brain region which subserves
learning, memory and neurodevelopmental processes [5], while ER-α are predominantly located in
the basal forebrain, which coordinates information processing and attentional function [5]. Therefore
deprivation of estrogen at menopause may contribute to the cognitive decline associated with
neurological ageing in both executive and memory functions [4]. Executive function governs high-level
cognitive functions such as time sharing, sequencing, response inhibition and perseverance, which is
crucial for independent living in older adults. In the context of independent living, executive and
memory functions are necessary for daily activities such as meal planning, paying bills, keeping
medical appointments and ambulation [5]. It is important to acknowledge that resveratrol may also act
through SIRT-1 and other mechanisms to increase NO bioavailability and boost cerebral vasodilator
responses to cognitive demands [6]. However, little attention has been given to the phytoestrogenic
nature of resveratrol and its potential to benefit postmenopausal women as a specific target population.
Epidemiological evidence indicates that hormone replacement therapy (HRT) halves the risk
of Alzheimer’s disease in postmenopausal women [7]. However, since publication of the Women’s
Health Initiative Study [8] the effects of HRT have been controversial. Five years of HRT use in
late postmenopause (>70 years old) resulted in increased risk of breast cancer, stroke, heart disease
and dementia, prompting many women to cease treatment and/or look for alternative treatment
for their menopausal symptoms. Since the publication of these disturbing findings, there has been
no follow-up investigation on whether cessation of HRT could lead to reduced risks. On the other
hand, clinical evidence has shown that estrogen administration can augment mood and cognitive
function postmenopausally, if commenced during early (peri) menopause rather than late menopause,
due to the profound effects of estrogen in the brain [9]. Progressive impairment of cerebrovascular
function is implicated in the pathogenesis of dementia [10]. Cerebrovascular responsiveness (CVR)
to hypercapnic provocation (a method of assessing endothelial health in the brain) is maintained in
women on HRT but is halved in non-HRT users [11]. Likewise, women with lower estrogen levels
have poorer cerebral perfusion, which is further compromised during a hot flush episode [12]. HRT
users exhibit higher hippocampal and temporal blood flow [measured by single positron emission
tomography), which correlates with better performance on memory tasks [13], suggesting that estrogen
plays a critical role in neurovascular and cognitive integrity. Impaired cerebral perfusion and executive
function also contribute to poor physical function, mood disorders and higher fall rates in older
adults [14]. CVR to hypercapnia was positively associated with gait speed and inversely related to
number of falls in the elderly [15]. Older adults with slow gait (<0.67 m/s) had poorer CVR while
performing the N-back task (a test of executive function) and had poorer test scores on executive
function tasks, compared to those with faster gait [16]. Thus more attention needs to be given to the
relationships between the neurovascular integrity and cognitive and physical impairments. Taken
together, the available evidence strongly supports the hypothesis that cognitive, mood and physical
deficits in older women may be attributed to impaired vascular function in the cerebral circulation.
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Thus maintenance of cerebrovascular function as part of healthy ageing may prevent the burden of
cognitive and physical disability in later life. Whether cognitive and physical function deficits in
postmenopausal women can be attenuated by improvement of cerebrovascular function is unknown.
1.2. How Could Resveratrol Benefit Postmenopausal Women?
Naturally occurring phytoestrogens such as those present in soy and red clover offer a potentially
safer alternative to HRT for postmenopausal health. Genistein from soy has been shown to improve
NO-mediated systemic vasodilator function in postmenopausal women [17] and thus may have the
potential to enhance cerebral perfusion which may in turn improve cognition and mood. Chronic soy
isoflavone supplementation has been shown to improve menopausally-related mood, memory, sleep
quality and vasomotor symptoms [18]. Moreover, it has also been shown to enhance spatial working
memory in young men (with low estrogen levels) [19]. However, its mechanisms of action are still
unknown and conflicting evidence has discouraged clinicians from recommending soy isoflavones to
menopausal women. Importantly, a large proportion of people lack the enzyme to convert daidzein
to equol, which (like genistein) mimics the action of estrogen on ER-β [20], which could explain the
variability in outcomes of soy interventions. In a recent study, administering 30 mg of pure (synthetic)
genistein significantly reduced hot flushes [21]. Considering that cerebral perfusion is compromised
during a hot flush episode [8], the improvement in menopausal symptoms may be partly attributable
to enhanced cerebrovascular function. However, this hypothesis has yet to be evaluated.
Resveratrol is a phytoestrogen found in grapes, berries and nuts with multiple targeted
benefits including cardiovascular and neurological, particularly attenuating learning impairment
and hippocampal degeneration [22]. It may act similarly to estrogen and genistein to confer
neurovascular protection by up-regulating eNOS activity, resulting in enhanced NO bioavailability and
vasorelaxation [23]. Resveratrol also rapidly stimulates the mitogen-activated protein kinase signalling
pathway via both ER-α and ER-β to increase eNOS activity in human endothelial cells at nanomolar
concentrations that can be achieved through habitual diet, e.g., a glass of grape juice [24]. Furthermore,
resveratrol can also reduce vascular tone via an endothelium-independent mechanism [23]. Given
that resveratrol is structurally similar to and mimics the activity of 17-β-estradiol, it may enhance
cognition by stimulating ERs [25] to increase perfusion via increased NO production. In human
trials, we and others have independently demonstrated its ability to improve endothelial vasodilator
function [26,27], cerebral perfusion and memory functions in older adults [28]. We found that
6-weeks daily supplementation with resveratrol (75 mg/day) resulted in a sustained improvement in
flow-mediated dilatation in the brachial artery in obese but otherwise healthy older adults. There was
also a non-statistical trend towards improvement in performance to the Stroop Test, suggesting that
perhaps a longer duration intervention might be needed to see enhancement in cognitive function [26].
A recent study found that daily supplementation (200 mg of resveratrol with 320 mg quercetin) for
6 months in older adults resulted in greater hippocampal activity at rest, assessed by MRI, and retention
of words learnt [28]. Whilst improvements in resting state activity may reflect enhancement in the
integrity and functionality of the hippocampus, this augmentation does not reveal whether resveratrol
can improve the efficiency of cerebral perfusion during cognitively demanding tasks, nor has it
been linked to enhanced cognitive performance, mood or physical function. Thus the potential for
resveratrol to maintain optimal cognitive health in postmenopausal women who are not taking HRT
must now be evaluated.
The primary aim of this study is to see whether daily supplementation with resveratrol for
14 weeks can improve cognition in postmenopausal women in whom age-related endothelial
dysfunction is exacerbated by estrogen deprivation. The secondary aim is to see whether improvements
in cognition, mood, physical function and aspects of well-being including sleep quality, quality of life,
menopausal symptoms and pain are accompanied by improvements in CVR to hypercapnia and/or to
cognitive demands.
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2. Materials and Methods
2.1. Study Design
A randomised, double-blind, placebo-controlled (parallel comparison) dietary intervention trial
of 14 weeks duration was designed to evaluate the effects of resveratrol supplementation (75 mg twice
daily) on cognitive abilities, CVR and overall well-being. The dose was based on data from an acute
dose response trial in those with type 2 diabetes mellitus (manuscript in preparation), in which
75 mg resveratrol elicited maximal CVR to hypercapnia when compared with 150 mg and 300 mg
doses. Assessments will be made at baseline (week 0) and at the end of the 14-week intervention
phase (week 14). The trial will be conducted at the Clinical Nutrition Research Centre, University
of Newcastle, in New South Wales, Australia in accordance with the Declaration of Helsinki and
Principles of Good Clinical Practice as outlined by the International Conference on Harmonisation.
The protocol has been approved by the University of Newcastle’s Human Research Ethics Committee
(H-2015-0002; approved on 13 March 2015) and registered with the Australia and New Zealand Clinical
Trials Registry on 27 March 2015 (ACTRN12615000291583).
2.2. Study Population
Healthy postmenopausal women from the general public residing in the Hunter region of
New South Wales were invited to participate following expressions of interest to approved newspaper
and radio campaigns. Each volunteer was first provided with an information statement outlining
the study objectives and procedures. A health and lifestyle questionnaire that collected information
pertaining to their menopausal status, medication and dietary supplement use and current perception
of their cognitive status was completed by interested parties. Upon returning the questionnaire, a study
investigator pre-screened volunteers via telephone to determine their potential suitability, as described
in Table 1, and to invite them in for a screening/baseline visit at the research centre. They were
also encouraged to consult with their medical practitioner regarding their intention to participate
in this intervention prior to their first visit. Written informed consent was obtained at start of the
screening/baseline visit.
Table 1. Eligibility criteria for the study.
Inclusion Criteria
‚ Aged 45–85 years
‚ Postmenopausal (self-reported cessation of menses for more than 6 months)
‚ Stable current medication (unlikely to change for duration of the study)
Exclusion criteria
‚ Currently taking HRT or alternative hormone therapy for the relief of postmenopausal symptoms or
have done so in the last 6 months
‚ Breast or cervical cancer
‚ Other serious disease, such as cardiovascular disease, other cancer, kidney or liver disease or
neurologic condition
‚ Smokers or currently on nicotine therapy
‚ Using insulin or warfarin therapy
‚ Clinically significant depression
‚ Currently consuming more than 4 alcoholic beverages a day
‚ Changed medication in the 3 months prior to study enrolment
‚ Clinic BP > 160/100 mmhg (determined at screening)
‚ Suspected dementia (determined at screening)
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Our power calculations (G*Power) [29] showed that 74 participants would give 80%
chance of detecting a statistically significant difference (p < 0.05) of medium effect size
(standardized difference = 0.67) in cognitive performance (composite score) between Resveratrol
and placebo treatments. To allow for attrition, we aimed to recruit 80 women.
2.3. Investigational Product and Allocation
The active and placebo capsules were of identical appearance and supplied by DSM Nutritional
Products Ltd, Switzerland. The active capsule comprised 75 mg of 99% pure synthetic trans-resveratrol.
The placebo comprised several inert excipients: calcium hydrogen phosphate, microcrystalline
cellulose, prosolv 50 and hydrated magnesium silicate. Two hundred capsules were each dispensed
in sealed white opaque containers and containers were identifiable only by code numbers.
An independent investigator who held the code list allocated participants to each treatment group
based on the minimisation method [30], to minimise differences between groups in age and years
since ceasing menses (obtained from their health and lifestyle questionnaires) prior to the scheduled
screening/baseline visit. The first participant was allocated randomly. Containers allocated to
volunteers who were subsequently deemed ineligible or did not attend the screening/baseline visit
were reassigned and the allocation list adjusted accordingly. Blinding will be maintained until all data
analysis has been completed.
2.4. Screening/Baseline Visit (Week 0)
Potentially eligible volunteers attended the 3-h screening/baseline visit after having refrained
for at least an hour from medication, food or beverages other than water. Height, weight and waist
circumference were measured followed by seated blood pressure (BP) readings to determine BP
eligibility. Dementia status was then assessed using the Australian version of the Mini-Modified
Mental State (3MS) examination. The 3MS is a widely used tool for screening suspected dementia;
a score of less than 78 was considered impaired and necessitated exclusion from the study [31].
Those who met the eligibility criteria were fitted with a Transcranial Doppler (TCD) ultrasound
headpiece to assess basal cerebral haemodynamics and CVR to both hypercapnic and cognitive
stimuli bilaterally in the middle cerebral artery (MCA). Participant’s performances were also recorded
during cognitive testing. At the conclusion of cognitive testing, participants underwent a hypercapnic
assessment of CVR in the posterior cerebral artery (PCA). A physical function assessment was then
carried out before a series of six paper-based questionnaires to assess mood and general wellbeing
were completed to conclude the visit. Figure 1 depicts the flowchart of the participants who were
enrolled in the study. It also highlights our study population size (n = 80, 40 per treatment group)
indicating that our treatment target has been reached.
2.5. Intervention and Follow-up (Week 0–14)
Participants were instructed to take two capsules of resveratrol daily, preferably at the same
time with meals, and to record each intake in the assigned supplement diary in order to assist with
treatment compliance. If a dose was missed, participants were able to catch up the same day but
discouraged from carrying over the dose to the next day. Participants were also encouraged to maintain
their habitual diet throughout the intervention; however any changes in dietary supplement and/or
medication intake during the intervention were to be recorded in the supplement diary. Participants
were also notified to contact the study investigators by phone if they experienced any out of the
ordinary side effects, became ill during the trial period or deviated from their habitual medication
use. Every four weeks participants were required to complete the Pittsburgh Sleep Quality and the
Menopausal Rating Scale in their supplement diaries.
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2.7. Outcome Assessments
Clinic Blood Pressure
Participants were rested for 10 min in a seated position. Four consecutive readings of BP were
taken at 2 min intervals; the first was discarded and the remaining averaged to obtain resting BP
(systolic, diastolic and mean arterial pressure) and heart rate for analysis. Measurements were taken
by automated oscillometry using an appropriately sized BP cuff placed over the brachial artery of the
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non-dominant hand (HDI Cardiovascular Profiler CR2000, Minnesota, MN, USA). BP measurements
were performed by a single investigator (H.M.E), in accordance with international guidelines [33].
2.8. Transcranial Doppler Ultrasound Assessements
Basal Cerebral Haemodynamics
TCD is a non-invasive technique that utilises ultrasound to assess blood flow velocity in the brain.
Using a TCD headpiece (Doppler-Box X, Singen, Germany), the MCA on both the left and right sides
were isolated using the transtemporal window as this provides the least interference during insonation.
The depth of insonation for MCA and PCA were between 45–60 mm and 60–70 mm respectively [34].
A 30-s of continuous recording of basal blood flow velocity in the MCA and PCA (maximum, minimum
and mean) were obtained before hypercapnic provocation and before the start of each cognitive test.
All basal blood flow velocities will be collated in spreadsheets and an average of the last 10 s of mean
blood flow velocity (x) will be reported for use in CVR calculations. The pulsatility index (PI) of the
MCA and PCA, reflecting stiffness in the cerebral vessels, is determined from the maximal velocity
minus the minimum velocity and divided by the mean velocity obtained during basal conditions.
2.9. Cerebrovascular Responsiveness
Increases in blood flow velocity in the MCA and PCA reflect the extent of endothelial dilation
in downstream anterior and posterior vessels respectively and thus is a good measure of CVR [35].
To assess CVR, participants inhaled a carbogen gas mixture (5% CO2, 95% O2) through a two-way
non-rebreathing mouthpiece for 180 s, resulting in an acute increase in blood flow velocity. The TCD
recorded bilateral beat-to-beat mean blood flow velocities during the hypercapnic provocation.
Our group has shown great reproducibility and thus the procedure was only repeated once for
reliability with a 2 min interval for washout.
The TCD headpiece was kept in position throughout the cognitive test battery to assess CVR to
cognitive stimuli in the MCA and was recorded during each cognitive task
Data will be stored on the computer hard drive until subsequent analysis. Each task, including
hypercapnia, recordings would be smoothed and analysed in TableCurve™ using data spline
estimation with Loess at 20% for hypercapnic assessment and 10%, for cognitive tasks, (TableCurve 2D
by Systat Software Inc., San Jose, CA, USA) to determine the peak increase in mean flow velocity (y).
CVR is calculated as a percentage using the equation
y´ x
x
ˆ 100.
2.10. Cognitive Performance
The neuropsychological test battery consisted of four tests, The Rey Auditory Verbal Learning
Test (RAVLT) [36], the Cambridge Semantic Memory Battery [37], the Double Span [38] and the Trail
Making Task (TMT) [39]. The composition of the test battery was chosen such that it would assess
those cognitive domains known to be negatively affected by reductions of circulating estrogen in
women, namely semantic [40], verbal [41] and visual spatial working memory [42,43] as well as
executive function, shown to decline with age irrespective of gender [44]. Importantly these tests also
reflect the ability to perform everyday tasks with a decline indicating a loss of independence in these
women. Table 2 outlines these tests, describing the cognitive domains targeted, the procedure and
scoring profiles.
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Table 2. Components of the Neuropsychological test battery.
Cognitive Test &
Domains Procedure Scoring
RAVLT
(immediate and
long-term verbal
memory)
Immediate: The participants were required to listen to an electronic audio containing 15 nouns (list A)
presented at a rate of 1 word/2 s. After the audio was played, participants were required to verbally
recall the words irrespective of order (trial A1). The list was presented a further four times (trial A2-A5).
A second interference list (list B) was presented in the same manner (trial B6). Immediately afterward
trial B6 participants were instructed to recall all the words from list A without prompt (trial A7).
Scaled scores = raw scores ´ errors
Learning = scaled total (Trials A1-A5).
Proactive memory = scaled Trial B6.
Delayed: participants performed other tasks for 20 min before being required to recall all 15 words from
list A (trial A8). Participants were then provided with a sheet containing all 15 words from both list A
and B as well as 20 words similar in either phonology or semantic terms (total 50 words) and required to
correctly identify words from both list A and list B. Retroactive interference = scaled trial
A7-scaled trial A5.
For each trial, number of errors was also recorded.
Delayed recall = scaled trial A8.
Recognition = Z-score list A + Z-score list B +
Z-score Errors
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Table 2. Components of the Neuropsychological test battery.
Cognitive Test &
Domains Procedure Scoring
Cambridge
Semantic
Memory Battery
(semantic
memory)
Category fluency: Participants were given 1 min to give as many items within a given category as they
could. 8 categories were used, separated into living (animals, fruits, Birds, breed of dogs) and non-living
(household items, tools, vehicles, types of boats)
Number of correct responses overall.
As per category fluency.Letter fluency: Participants were given 1 min to give as many words as they could starting with a given
letter. Letters used were F, A and S. Proper nouns were excluded.
Naming: participants were required to correctly name 64 images of common living and non-living items,
presented one by one.
As per category fluency.
Category Comprehension: Participants were read the names of 64 items and required to correctly identify
each from groups of images closely related to the stimuli.
Semantic Association (camel and cactus): Participants were shown an item and must correctly identify,
from a separate group of 4 items, the item that is best associated with the first.
As per category fluency.
As per category fluency.
Double Span
Task (visuospatial
working memory)
14 different objects were used in this task. For each task, a random number of objects (max = 5)
displayed in random positions on 4 ˆ 4 grid. Participants were prompted to either recall positions
(point to position of each object in the order they were presented) or positions and names (point to the
position of each object in the order they were presented saying the name of each object verbally) in an
empty grid after a 5 s delay.
“Positions” = number of each correct
position in order.
“Position and names” as per “positions”
with an additional mark for each correct
name in order.
Marks were then tallied for an overall score.
Trail Making
Task (executive
function and
processing speed)
Trial A: Participants were required to draw a continuous line connecting 25 numbers spread randomly
across the page in ascending order. Trial A and B = Time taken, errors
Trial B: Participants were required to draw a continuous line alternating between numbers and letters
(1,a,2,b,3,c, etc.) spread randomly across the page Interference = time taken (trial B/Trial A)
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2.11. Assessment of Mood
Participant’s mood states were assessed using two different indexes, the Profile of Mood
States (POMS-V2) and the Center for Epidemiological Studies Depression Scale (CES-D). The POMS
questionnaire assessed how the participant was feeling over the last week including the day of the
visit through 65-adjectives that the participant rated on a 5-point Likert scale (1 being “not at all” and
5 being “extremely”). The POMS Standard has proven to be an excellent measure of mood states and
their fluctuations [45]. The CES-D scale is a commonly used tool to characterize depressive symptoms
in the general population [46] and the sensitivity ideal for detecting depression in postmenopausal
women [47]. The 20-item scale measures major depressive symptomatology of participants, including
depressive mood, feelings of guilt and worthlessness, psychomotor retardation, loss of appetite and
sleep disturbances.
2.12. Physical Function Assessment
The physical function test battery is a validated measure of functional performance of daily living
activities in community living older adults consisting of nine tasks [48]. For each task, the time taken
to complete was recorded. Participants were required to write a legible sentence, mimic eating by
picking up kidney beans with a teaspoon from a bowl and placing them in another while they remain
stationary, lifting a heavy book from waist level and placing on a cabinet at shoulder level while
remaining seated, put on and remove a coat (A standard lab coat was used to maintain consistency),
pick up a 50 cent coin from the floor, pivot 360˝, walk 15 metres and climb flights of stairs. Assistive
devices are permitted in the locomotive tasks. Higher scores equated to better performances.
2.13. Assessment of Overall Well-Being
Overall wellbeing was assessed through a series of four different questionnaires, designed to
assess varying aspects of a participant’s general living. Participant’s pain symptomatology was
assessed through the Short-form McGill Pain questionnaire [49]. Sleep quality was assessed through
the Pittsburgh Sleep Quality Index [50], Menopausal symptoms were assessed using the Menopausal
Rating Scale (MRS) as this has been shown to be effective in measuring treatment effects on quality
of life across the full range of severity of complaints in ageing women [51] and the participants own
perception of their physical and mental health were also recorded using the Short-form 36 (SF-36)
Health Survey, a validated questionnaire in menopausal women [52].
2.14. Statistical Analysis
The primary outcome is the effect of resveratrol supplementation versus placebo on cognitive
performance, determined using a composite score of all memory tests. Treatment by time effects will
be determined by analysis of variance (ANOVA), or analysis of covariance (ANCOVA) in the event
of interacting variables. the process of subject allocation by minimisation will have balanced age
and years since cessation of menses between groups; however other baseline characteristics such as
clinic BP, basal PI, BMI, 3MS score and years of education will be considered covariates if they were
significantly correlated with the primary outcome.
Treatment changes in CVR to hypercapnia and/or cognitive stimuli, improvements in physical
function, mood states and quality of life will be assessed using linear regressions with false rate
discovery adjustments used to minimise type 1 error. In addition, to explore the potential benefits
of early intervention, the magnitude of improvement following resveratrol supplementation will be
compared in early (<10 years) and late (>10 years) postmenopausal women. Statistical significance for
the primary outcome is set at p < 0.05 and false discovery rate will be applied to secondary outcomes.
Statistical analyses will be performed using SPSS version 21.0 (SPSS by IBM Inc., Chicago, IL, USA).
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3. Conclusions
We have identified postmenopausal women as a vulnerable population at increased risk of
cognitive decline and dementia who may benefit from supplementing their diet with resveratrol.
This paper provides a rationale for investigating the effects of resveratrol supplementation on
cognitive performance and mood in postmenopausal women based on our hypothesis that
resveratrol can augment both by enhancing cerebrovascular perfusion. According to our hypothesis,
any improvements in cognition will be secondary to improvements in CVR; however, the technical
limitations of obtaining reliable TCD ultrasound signals, particularly in older women, did not warrant
the inclusion of cerebrovascular function as the primary outcome as recruitment may be limited.
Nonetheless it provides a detailed study design and protocol for undertaking this investigation,
utilising TCD as a novel approach to evaluate impacts of supplementation on CVR. Additionally,
through this paper we have outlined a model approach for which we can establish a portfolio of
evidence for the efficacy of not only resveratrol but other vasoactive nutrients in maintaining optimal
circulatory function to ameliorate the risk of developing dementia.
Given that resveratrol supplements are readily available over-the-counter to consumers,
the anticipated outcomes will offer a non-pharmaceutical approach for managing menopause-related
symptoms and counteracting accelerated cognitive and physical decline as well as mood disorders in
women postmenopausally, which can be readily implemented by clinicians and the public.
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